<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TRC-14004196</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2014-01-24</date_registration>
      <primary_sponsor>Department of Hematology, the First Affiliated Hospital of Soochow University</primary_sponsor>
      <public_title>Haplo-mismatch Donor Stem Cell Transplantation (SCT) versus Autologous SCT followed or not by maintenance therapy, for Patients with Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study</public_title>
      <acronym />
      <scientific_title>Haplo-mismatch Donor Stem Cell Transplantation (SCT) versus Autologous SCT followed or not by maintenance therapy, for Patients with Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2014-01-01</date_enrolment>
      <type_enrolment />
      <target_size>haplo-SCT:106;ASCT:106;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=5372</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>IV (Phase IV study)</phase>
      <hc_freetext>Acute Myeloid Leukemia</hc_freetext>
      <i_freetext>haplo-SCT:undergo haplo-SCT;ASCT:undergo ASCT;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>CHEN Jia</firstname>
        <middlename />
        <lastname />
        <address>188 Shizi Street, Suzhou, Jiangsu, China</address>
        <city />
        <country1 />
        <zip>215006</zip>
        <telephone>+86 0512-67781856</telephone>
        <email>c_jerry_j@163.com</email>
        <affiliation>Department of Hematology, the First Affiliated Hospital of Soochow University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>WU Depei</firstname>
        <middlename />
        <lastname />
        <address>188 Shizi Street, Suzhou, Jiangsu, China</address>
        <city />
        <country1 />
        <zip>215006</zip>
        <telephone>+86 0512-67781856</telephone>
        <email>wudepei@medmail.com.cn</email>
        <affiliation>Department of Hematology, the First Affiliated Hospital of Soochow University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Aged 18 year and more;
2. Diagnosed as AML (except acute promyelocytic leukemia M3) for the first time;
3. Minimal Residual Disease (MRD) test can be achieved (molecular biology first if applicable, and/or cytogenetics and/or immunophenotyping);
4. Presence of an available haplo-mismatch related donor.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>100</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Contra-indications of chemotherapy or  hematopoietic stem cell transplantation;
2. Presence of an available identical sibling donor or a 10/10 HLA loci-matched unrelated donor;
3. Participating in other clinical trials concerning the prophylaxis of disease recurrence after ASCT;
4. No effective contraception;
5. Pregnant or lactating females;
6. Other causes which are not suitable for the trial in investigator's consideration.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Leukemia Free Survival;Non-relapse Mortarlity;Incidence of Engraftment;Quality of Life;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Overall Survival;Relapse Incidence;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Supported by Jiangsu Province’s Key Medical Center (ZX201102); National Public Health Grand Research Foundation (No.201202017); National High-tech R&amp;D Program (863 Program) (2012AA02A505）</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-12-10</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>